HomeNewsScreenerChartsMapsGroupsPortfolioInsiderFuturesForexCryptoCalendarPricing
Theme 		Help

New Elite Feature: Chart Templates — Your indicators and design everywhere on Finviz

Learn More
Market News Market Pulse Stocks News ETF News Crypto News

ALTERITY THERAPEUTICS LIMITED

Contributing Author

Recent Articles by ALTERITY THERAPEUTICS LIMITED

Mar-30
Alterity Therapeutics Receives Positive FDA Feedback Following Type C Meeting on ATH434 Phase 3 Program ATHE +12.97% GlobeNewswire
Mar-09
Alterity Therapeutics to Participate in the Bell Potter Healthcare Horizons Summit ATHE GlobeNewswire
Mar-04
Alterity Therapeutics Appoints Daniel O. Claassen, M.D., M.S., as Chief Medical Advisor ATHE GlobeNewswire
Mar-02
Alterity Therapeutics Recognizes Multiple System Atrophy (MSA) Awareness Month in March and the Urgent Need for Disease-Modifying Treatments ATHE GlobeNewswire
Jan-30
Alterity Therapeutics: Appendix 4C - Q2 FY26 Quarterly Cash Flow Report & Corporate Update ATHE GlobeNewswire
Jan-21
Alterity Therapeutics Issues Shareholder Letter Highlighting 2025 Progress and Key Objectives for 2026 ATHE GlobeNewswire
Nov-12
Alterity Therapeutics to Present at the Bell Potter Healthcare Virtual Conference ATHE GlobeNewswire
Nov-10
Alterity Therapeutics Presents Promising Impact of ATH434 on Orthostatic Hypotension and Disease Progression in MSA at the 36th International Symposium on the Autonomic Nervous System ATHE +8.27% GlobeNewswire
Oct-31
Alterity Therapeutics: Appendix 4C - Q1 FY26 Quarterly Cash Flow Report ATHE -8.48% GlobeNewswire
Oct-09
Alterity Therapeutics Presents Positive Data from ATH434 Phase 2 Trial at the 2025 International Congress of Parkinson's Disease and Movement Disorders ATHE GlobeNewswire
Oct-02
Alterity Therapeutics to Deliver Multiple Presentations at the 2025 International Congress of Parkinson's Disease and Movement Disorders ATHE +6.08% GlobeNewswire
Sep-15
Alterity Therapeutics Presents ATH434-201 Phase 2 Data at the American Neurological Association Annual Meeting ATHE GlobeNewswire
Sep-08
Alterity Therapeutics Raises A$20.0 million in Strategic Placement ATHE GlobeNewswire
Sep-02
Alterity Therapeutics to Present at the Biotech Showcase ATHE GlobeNewswire
Jul-30
Appendix 4C - Q4 FY25 Quarterly Cash Flow Report ATHE GlobeNewswire
Jul-28
Alterity Therapeutics Reports Positive Topline Data from Open-Label Phase 2 Clinical Trial of ATH434 in Multiple System Atrophy ATHE -14.81% GlobeNewswire
Jul-24
Alterity Therapeutics Announces Publication on Novel MRI Endpoint from the bioMUSE Natural History Study ATHE +13.76% GlobeNewswire
Jun-23
Alterity Therapeutics to Provide Corporate Update in Fireside Chat ATHE GlobeNewswire
May-12
Alterity Therapeutics Prominently Featured at the International MSA Congress ATHE -8.54% GlobeNewswire
May-07
Alterity Therapeutics Announces Multiple Oral and Poster Presentations to be Featured at the International MSA Congress ATHE GlobeNewswire
May-05
Alterity Therapeutics Granted U.S. FDA Fast Track Designation for ATH434 to Treat Multiple System Atrophy ATHE +26.45% GlobeNewswire
Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)